ErbB2/Her2 antibody (Alexa Fluor 647)

Catalog No. ABIN2657764

The Mouse Monoclonal anti-ErbB2/Her2 antibody has been validated for FACS. It is suitable to detect ErbB2/Her2 in samples from Human.

Quick Overview for ErbB2/Her2 antibody (Alexa Fluor 647) (ABIN2657764)

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ErbB2/Her2 antibody is conjugated to Alexa Fluor 647

Application: Flow Cytometry (FACS)

Clone: 24D2

Product Details anti-ErbB2/Her2 Antibody (Alexa Fluor 647)

Purification: The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C

Target Details for ErbB2/Her2

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Alternative Name: CD340

Background: CD340 is also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. It is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain and has an approximate molecular weight of 185 kD. CD340 contains three furin repeats and two cheY homologous receiver domains in the extracellular region (ECR). The HER2/erbB2 protein is expressed on many tumor cells, including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow mesenchymal stem cells. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression, this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Overexpression of erbB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).

Pathways: RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development